Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Launches Let Hikma Cope With Competition On US Injectables

Executive Summary

A stream of launches, including of vancomycin as its 100th injectable medicine in the US, is helping Hikma’s Injectables business segment to more than offset the effects of increased competition.

You may also be interested in...



Hikma Starts Seeing Benefits Of Stepping In On US Shortages

Helping to alleviate shortages of critical US injectables, including controlled substances, has strengthened Hikma’s relationships with its hospital customers in the US, including with Civica Rx, CEO Siggi Olafsson told Generics Bulletin.

Hikma Plans to Partner Away From Branded Generics Focus In MENA

With local competitors in the MENA region increasingly able to compete on branded generics, Jordan’s Hikma is shifting the focus of its local operation towards partnering for patent-protected products.

Hikma Sees Field For Generic Of Advair Narrow As It Enrols Study

The challenges of developing a US generic of GlaxoSmithKline’s Advair Diskus fluticasone/salmeterol asthma blockbuster are thinning the field and improving the commercial prospects for those that succeed, Hikma believes.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB140342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel